3.175
Arbutus Biopharma Corp stock is traded at $3.175, with a volume of 372.43K.
It is down -1.09% in the last 24 hours and down -3.20% over the past month.
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
See More
Previous Close:
$3.21
Open:
$3.25
24h Volume:
372.43K
Relative Volume:
0.39
Market Cap:
$595.61M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.2159
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+0.47%
1M Performance:
-3.20%
6M Performance:
-21.22%
1Y Performance:
+20.27%
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ABUS
Arbutus Biopharma Corp
|
3.175 | 595.61M | 12.99M | -74.39M | -78.92M | -0.44 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.15 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
583.23 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.94 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.89 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.05 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
Feb-25-21 | Initiated | Jefferies | Hold |
Dec-17-20 | Initiated | H.C. Wainwright | Buy |
Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Feb-20-20 | Initiated | Robert W. Baird | Outperform |
Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
Oct-07-19 | Reiterated | B. Riley FBR | Buy |
Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Feb-01-17 | Reiterated | Wedbush | Outperform |
Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Alliancebernstein L.P. Has $393,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Franklin Resources Inc. Takes $301,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Wellington Management Group LLP Buys 16,484 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Corebridge Financial Inc. Has $238,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
KLP Kapitalforvaltning AS Invests $84,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Teacher Retirement System of Texas Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Warminster-Based Arbutus Biopharma Lays Off Over Half of Workforce, Exits Its Headquarters - BUCKSCO.Today
Moderna (NasdaqGS:MRNA) Faces Legal Spotlight Affecting Investor Sentiment with -8% Dip Over Last Month - Yahoo Finance
Arbutus Biopharma Corp (NASDAQ: ABUS) – An Analysis Is What You Need - stocksregister.com
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MSN
Xponance Inc. Takes $34,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Chardan Capital Reiterates “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Trading 4.1% Higher Following Strong Earnings - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com
Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha
Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - uspostnews.com
Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks
Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN
Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Moderna (NasdaqGS:MRNA) Sees 15% Jump Despite Recent Revenue Challenges - Yahoo Finance
FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World
Are Arbutus Biopharma Corp’shares a good deal? - US Post News
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction - Yahoo Finance
Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360
Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire
Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq
Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat
Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat
Brokers Set Expectations for ABUS FY2029 Earnings - Defense World
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo
Lindsay Androski named CEO of Arbutus - BioCentury
Arbutus Biopharma appoints new CEO and reshapes board - Investing.com
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):